VX18-445-110: A Phase 3, Open-label Study Evaluating the Long term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)


This is an open-label study for patients rolling over from VX18-445-104. This study will evaluate the long-term safety and efficacy of VX-445 combination therapy in subjects with CF.

I'm interested

12 Years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Completed study drug treatment in parent study (VX18-445-104); or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study Key
Exclusion Criteria:

• History of study drug intolerance in parent study Other protocol defined Inclusion/Exclusion criteria may apply

Drug: ELX/TEZ/IVA, Drug: IVA

Cystic Fibrosis

Mary Bailey -
Joanne Billings
Phase 3
See this study on